Clinically desirable drug interactions.
D000617:Aminoglycosides / Q000627:therapeutic use; D000658:Amoxicillin / Q000627:therapeutic use; D000667:Ampicillin / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D002230:Carbidopa / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007008:Hypokalemia / Q000517:prevention & control; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010406:Penicillins / Q000627:therapeutic use; D011339:Probenecid / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000617:Aminoglycosides; D000863:Antacids; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004232:Diuretics; D004338:Drug Combinations; D006877:Hydroxamic Acids; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D010406:Penicillins; D007980:Levodopa; C006358:acetohydroxamic acid; D000667:Ampicillin; D000658:Amoxicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002230:Carbidopa; D011339:Probenecid